黏液性卵巢癌的治疗选择:基因组分析
该研究分析191例原发黏液性卵巢癌的基因拷贝数与测序数据,评估靶向治疗潜力。结果显示ERBB2扩增占26.7%、BRAF突变9%、KRAS/NRAS突变66%,而HRD高分仅1/191、错配修复缺陷仅1/184,提示PARP抑制剂和铂类疗效有限。
要点
- MOC中ERBB2扩增26.7%、BRAF突变9%,提示可用相应靶向药。
- KRAS/NRAS突变66%、TP53错义突变49%,为潜在试验靶点。
- HRD高分仅1/191、错配修复缺陷仅1/184,PARP抑制剂可能无效。
核心结论
- MOC虽基因组多样但存在多个潜在治疗靶点,HRD和错配修复缺陷罕见,与铂类临床反应差相符且PARP抑制剂可能无效。
研究设计与样本
- 分析191例原发MOC的基因拷贝数及184例DNA测序数据,并收集117-166例免疫组化数据。
主要发现
- ERBB2扩增占26.7%,BRAF突变占9%。
- KRAS/NRAS突变占66%,TP53错义突变占49%,RNF43突变占11%,ARID1A突变占10%,PIK3CA/PTEN突变占9%。
- HRD高分仅1/191,错配修复缺陷仅1/184。
临床怎么用
- 对复发或晚期MOC可基于ERBB2扩增、BRAF突变等分子标志探索靶向治疗。
- HRD和错配修复缺陷罕见,不建议常规使用PARP抑制剂或免疫检查点抑制剂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Mucinous ovarian carcinoma (MOC) is an uncommon ovarian cancer histotype that responds poorly to conventional chemotherapy regimens. Although long overall survival outcomes can occur with early detection and optimal surgical resection, recurrent and advanced disease are associated with extremely poor survival. There are no current guidelines specifically for the systemic management of recurrent MOC. We analyzed data from a large cohort of women with MOC to evaluate the potential for clinical utility from a range of systemic agents. METHODS: We analyzed gene copy number (n = 191) and DNA sequencing data (n = 184) from primary MOC to evaluate signatures of mismatch repair deficiency and homologous recombination deficiency, and other genetic events. Immunohistochemistry data were collated for ER, CK7, CK20, CDX2, HER2, PAX8 and p16 (n = 117-166). RESULTS: Molecular aberrations noted in MOC that suggest a match with current targeted therapies include amplification of ERBB2 (26.7%) and BRAF mutation (9%). Observed genetic events that suggest potential efficacy for agents currently in clinical trials include: KRAS/NRAS mutations (66%), TP53 missense mutation (49%), RNF43 mutation (11%), ARID1A mutation (10%), and PIK3CA/PTEN mutation (9%). Therapies exploiting homologous recombination deficiency (HRD) may not be effective in MOC, as only 1/191 had a high HRD score. Mismatch repair deficiency was similarly rare (1/184). CONCLUSIONS: Although genetically diverse, MOC has several potential therapeutic targets. Importantly, the lack of response to platinum-based therapy observed clinically corresponds to the lack of a genomic signature associated with HRD, and MOC are thus also unlikely to respond to PARP inhibition.
引用
- Gorringe KL, Cheasley D, Wakefield MJ, et al. Therapeutic options for mucinous ovarian carcinoma. Gynecol Oncol. 2020. PMID: 31902686. doi:10.1016/j.ygyno.2019.12.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。